Sun Pharma Advanced Research Company growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+2,518.3%−5.0%−69.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+594.8%+19.6%—
+573.4%+19.1%—
+553.5%+11.5%—
+553.6%+11.6%—
+547.0%−34.9%−38.0%
+717.1%−272.5%−75.5%
+33.7%+16.1%−521.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹5,938 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-69.7-5.0+2,518.3—
EBITDA Growth——+19.6+594.8—
EBIT Growth——+19.1+573.4—
Net Income Growth——+11.5+553.5—
EPS Growth——+11.6+553.6—
Total Assets Growth—-38.0-34.9+547.0—
Total Equity Growth—-75.5-272.5+717.1—
Cash from Operations Growth—-521.0+16.1+33.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.